Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

88.95USD
20 Apr 2018
Change (% chg)

$-0.67 (-0.75%)
Prev Close
$89.62
Open
$89.42
Day's High
$90.13
Day's Low
$88.27
Volume
3,092,993
Avg. Vol
2,484,638
52-wk High
$147.13
52-wk Low
$84.29

Select another date:

Thu, Apr 19 2018

BRIEF-Celgene Announces Changes To Its Board Of Directors

* CELGENE CORPORATION ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

Continue Reading

Celgene Chief Operating Officer Scott Smith abruptly resigns

Celgene Corp said on Monday Chief Operating Officer Scott Smith is leaving the company, effective immediately.

Celgene Chief Operating Officer Scott Smith abruptly resigns

April 2 Celgene Corp said on Monday Chief Operating Officer Scott Smith is leaving the company, effective immediately.

Judge allows Celgene whistleblower to be paid after bitter fee fight

A federal judge has cleared the way for an ex-Celgene Corp employee to collect nearly $72.6 million as her cut of a $280 million settlement with the drugmaker after striking a lien her former law firm Grant & Eisenhofer placed on the payout.

BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.

* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES

BRIEF-Abide And Celgene Enter Worldwide License Agreement For ABX-1772

* ABIDE AND CELGENE ENTER WORLDWIDE LICENSE AGREEMENT FOR ABX-1772

Parents’ lawsuit claims Celgene unit used child as ‘guinea pig’ in phase II drug trial

A couple whose daughter died during a phase II clinical study of a novel cancer drug has filed a wrongful death suit against Celgene Corp's recently acquired Juno Therapeutics Inc, saying the company used the woman as a "human guinea pig" to quickly bring the drug to market.

BRIEF-Prothena Announces Global Neuroscience Research & Development Collaboration With Celgene

* PROTHENA ANNOUNCES GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE FOR NOVEL THERAPIES FOR PATIENTS WITH NEURODEGENERATIVE DISEASES

BRIEF-Celgene Completes Acquisition Of Juno Therapeutics

* CELGENE COMPLETES ACQUISITION OF JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY Source text for Eikon: Further company coverage:

Dollar rises on Powell's economic outlook, stocks slip

NEW YORK The dollar rose to five-week highs on Wednesday on the prospect of tighter monetary policy and an upbeat U.S. economic outlook from the Federal Reserve's new chief, while global equity markets slid on declines by China's Tencent and Celgene Corp.

Select another date:

Market Views

» More CELG.OQ Market Views